Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or North Carolina for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to North Carolina only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. North Carolina (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Zeina Haddad (NPI 1821251802)

Field	Value
Entity Type	Individual
Organization	Zeina Haddad
Address	2170 Midland Rd
City	Southern Pines
State	NC
ZIP	28387
Taxonomy	Ophthalmology Physician
NPI Enumerated	July 9, 2008

Payer Source	Total Paid
Medicare	$2.7M
Medicaid	$0

Key Findings

Practice is heavily retina-focused and driven by intravitreal therapeutics: the top three Medicare revenue codes are all injectable retinal drugs — J0178 ($1M; aflibercept), J2777 ($612.5K; faricimab), and J2778 ($545.3K; ranibizumab) — and these three codes together account for 80.8% of this provider's total Medicare revenue. Procedural and diagnostic codes that support retina care (e.g., 92134 OCT imaging and 67028 intravitreal injection procedure) also appear on the top list, consistent with a practice model centered on frequent injections and image-based monitoring.

Revenue concentration is high: the precomputed top-3 share of 80.8% signals that the provider’s Medicare revenue is largely dependent on a small set of high-cost biologic injections (J0178, J2777, J2778). That concentration implies sensitivity of the provider’s revenue to changes in utilization or reimbursement for those specific agents and to shifts in clinical preference among anti-VEGF and related therapies.

Payer mix is effectively single-payer Medicare: lifetime Medicare revenue is $2.7M while there is no Medicaid billing on file, meaning the provider operates with virtually no Medicaid-reimbursed volume. This absence of Medicaid activity suggests a patient panel or contracting footprint that is concentrated in the Medicare population rather than dual Medicare/Medicaid practices.

Competitive standing for individual drugs is mixed: J0178 ranks #840 of 3204 (74th percentile) and J2777 ranks #494 of 2039 (76th percentile), both described as typical, unremarkable national volumes, indicating modest market presence for aflibercept and faricimab. By contrast, J2778 (ranibizumab) ranks #116 of 1208 (90th percentile), placing the provider toward the upper tier nationally for that specific agent and reflecting relatively higher ranibizumab utilization than peers.

Certain services are statistical outliers or notably high-volume relative to peers: 92134 (OCT imaging) is listed as an "extreme outlier, far above typical national volume" at the 98th percentile with 2.8K claims, signaling unusually heavy imaging throughput. Similarly, J7312 (dexamethasone intravitreal implant) ranks #21 of 492 (96th percentile; notably above typical national volume), indicating above-typical use of steroid implants in addition to anti-VEGF therapy.

Office visit and follow-up volumes are above typical national levels: 99214 (640 claims) ranks #31446 of 479517 (93th percentile; notably above typical national volume) and 99213 (873 claims) ranks #8837 of 457151 (98th percentile; notably above typical national volume). Those elevated E/M percentiles are consistent with frequent follow-up visits required for ongoing retinal injection regimens and monitoring.

The practice carries a mix of medical and some surgical retina activity but at lower volumes: procedures such as 67042 (vitrectomy; 14 claims, $11.9K) and other laser procedures (e.g., 67210, 67228) appear on the code list but represent much smaller shares of revenue compared with intravitreal drug codes. This pattern indicates primary emphasis on outpatient injection management and imaging with occasional surgical interventions.

Established NPI tenure supports interpretation of stable practice patterns: the provider’s NPI was enumerated on 2008-07-09 (~18 years ago), consistent with a long-standing ophthalmology practice. For payers and provider network planners, the combined profile (high reliance on anti-VEGF/faricimab/ranibizumab therapies, heavy OCT use, elevated E/M volume, and no Medicaid billing on file) signals a mature, Medicare-focused retina specialty that will likely generate predictable injectable and imaging utilization.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

16 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0178	Injection, aflibercept, 1 mg	1,470	$680	$1M
J2777	Injection, faricimab‑svoa, 0.1 mg	21,120	$30	$612.5K
J2778	Injection, ranibizumab, 0.1 mg	3,000	$180	$545.3K
67028	The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye.	1,620	$90	$145.6K
J7312	Injection, dexamethasone, intravitreal implant, 0.1 mg	630	$160	$99.5K
92134	The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes.	2,810	$30	$81.6K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	640	$90	$58.2K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	870	$60	$51.5K
92235	The provider uses a special dye, fluorescein that causes the blood vessels in the one or both eyes to stand out in photographic images taken with the use of multiframe timing, or serial images, taken…	150	$100	$14.5K
67210	The provider destroys a lesion of the retina using a laser beam that heats up the tissue.	30	$370	$12.7K

Showing 1–10 of 16

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 16 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. North Carolina Distribution

Zeina Haddad — 3 of 16 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — North Carolina

Full comparison — all codes billed, vs. state median

16 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0178	33	100	950	$690	$881K
J2777	27	70	12,990	$30	$503.7K
J2778	3	50	620	$180	$202.2K
67028	26	120	780	$90	$80K
J7312	2	20	390	$160	$56.4K
67042	19	30	20	$990	$23.8K
99214	936	18,060	110	$80	$15.1K
J9035	31	90	140	$50	$13.4K
92235	10	70	60	$100	$8.7K
67210	2	10	10	$390	$8.5K

Showing 1–10 of 16

Related Providers

Other providers that share a Tax Identification Number (TIN) with Zeina Haddad, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Arghavan Almony	NC	Ophthalmology Physician	$3.9M	$0
Kendall Wannamaker	NC	Ophthalmology Physician	$2.7M	$0
Paula Pecen	NC	Ophthalmology Physician	$1.1M	$0
Neil Griffin	SC	Ophthalmology Physician	$800.4K	$0
John French	NC	Ophthalmology Physician	$453.7K	$0
Tarra Millender	NC	Ophthalmology Physician	$391.9K	$0
Anna Fakadej	NC	Ophthalmology Physician	$386.1K	$0
Jeffrey White	NC	Ophthalmology Physician	$385.5K	$0
Winston Garris	NC	Ophthalmology Physician	$304.6K	$0
Robert Sharpe	NC	Ophthalmology Physician	$257.3K	$0

Nearby Providers

Other providers in the same ZIP code as Zeina Haddad, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Sandhills Pediatrics	NC	Pediatrics Physician	$0	$32.8M
Integrated Pain Solutions PLLC	NC	Interventional Pain Medicine Physician	$0	$12.7M
Magnolia Gardens	NC	Assisted Living Facility	$0	$8.3M
The Eye Surgery Center Of The Carolinas LP	NC	Ambulatory Surgical Clinic/Center	$3.1M	$813.9K
Brooks Mays	NC	Endocrinology, Diabetes & Metabolism Physician	$569.7K	$0
Michol Stanzione	NC	Internal Medicine Physician	$433.8K	$0
Scott Luneau	NC	Internal Medicine Physician	$335.7K	$0
Robert Deucher	NC	Internal Medicine Physician	$323.7K	$0
Andrew Apple	NC	Optometrist	$236.3K	$0
Lisa Sitterson	NC	Ophthalmology Physician	$190.8K	$0

Zeina Haddad — Billing Profile & Reimbursement Data

Sign up for Zeina Haddad — Billing Profile & Reimbursement Data policy alerts

Zeina Haddad — Billing Profile & Reimbursement Data

Sign up for Zeina Haddad — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References